bioAffinity Technologies Sees Surge in CyPath® Lung Test Sales

bioAffinity Technologies, Inc. ( (BIAF) ) has issued an update.

On August 13, 2025, bioAffinity Technologies announced a significant increase in sales of its CyPath® Lung test, with July’s test volume surging 72% over the prior monthly average. Despite this growth, the company faces potential delisting from the Nasdaq Capital Market due to non-compliance with listing requirements, but plans to appeal the decision to stay its securities’ suspension.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.

The score reflects significant financial challenges and poor valuation metrics. However, recent positive corporate developments, including international patent approvals and successful product tests, provide potential growth opportunities. Technical indicators suggest stability in the short term, but financial instability and Nasdaq compliance issues present notable risks.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics and early cancer detection. Its flagship product, CyPath® Lung, is a noninvasive test for early-stage lung cancer, marketed as a Laboratory Developed Test by its subsidiary, Precision Pathology Laboratory Services.

Average Trading Volume: 7,205,393

Technical Sentiment Signal: Sell

Current Market Cap: $7.8M

For a thorough assessment of BIAF stock, go to TipRanks’ Stock Analysis page.